Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [QUIET] · [HEALTH]
2 clusters · 13 sources · 26 days · First seen · Last updated
Myasthenia gravis research and treatment in Italy
Overview
Efforts to manage and understand Myasthenia gravis, a rare autoimmune disease causing muscle weakness, have progressed through various clinical initiatives in Italy.
Initial efforts included the ‘Training Xperience’ project, a field training initiative involving three major neurological centers in Lombardy. This project focused on personalizing therapeutic pathways and integrating different treatment modalities into clinical practice.
Building on these efforts, the Poema study was launched to gather real-world evidence on the disease. This prospective study evaluates the response to efgartigimod treatment while examining psychological well-being, autonomy, and quality of life. The research involves 40 reference centers across Italy and monitors 100 patients over a 12-month period.
At the 56th Congress of the Italian Society of Neurology, new findings from a multicenter study involving 14 centers were presented by neurologist Nicasio Rini. The research indicates that zilucoplan, a complement inhibitor, effectively improves patients' clinical conditions and quality of life. The treatment has been associated with a ‘progressive reduction in daily corticosteroid dosages’ and a ‘drastic decrease in hospitalizations and rescue therapies’.
Entities
Italian Society of Neurology · Ospedale Papa Giovanni XXIII · Laura Boffa · Policlinico Tor Vergata · Yuri Matteo Falzone
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 3 SOURCES] The Poema study is a prospective real-world evidence research project in Italy.
- [● 3 SOURCES] The study evaluates the response to efgartigimod treatment.
- [● 3 SOURCES] The research involves 40 reference centers across Italy.
- [● 3 SOURCES] The study includes 100 recruited patients.
- [● 3 SOURCES] Patients will be followed for a period of 12 months.
- [● 3 SOURCES] Enrollment for the study has reached 50 percent.
- [● 3 SOURCES] An Investigator Meeting was held in Turin to share progress.
- [● 3 SOURCES] Myasthenia Gravis is an autoimmune disease causing muscle weakness and fatigue.
Timeline
-
[HEALTH] 13 sourcesItaly advances research and treatments for Myasthenia Gravis
Italian medical researchers are reporting improved patient outcomes with zilucoplan and launching the Poema study to evaluate the socio-sanitary and psychological impacts of efgartigimod on Myasthenia Gravis.
-
[HEALTH] 3 sourcesMyasthenia gravis affects 15,000 people in Italy
Myasthenia gravis affects over 15,000 people in Italy. New clinical training initiatives in Lombardy aim to improve care through personalized treatment and better monitoring of this chronic autoimmune disease.
Sources
codirp.it · corcianonline.it · egnews.it · forchecaudine.it · ilsannioquotidiano.it · lagazzettatorinese.it · lsdmagazine.com · notiziedi.it · periodicodaily.com · senzalinea.it · technoblitz.it · trapanisi.it · vetrinatv.it
This summary has been updated 1 time: see revision history